Nomad Power Solutions (STU:8640) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:8640 Nomad Power Solutions Inc STU:8640
34 GF Score
Price €6.00
! 1 Warning Sign
View Full Analysis

What is Nomad Power Solutions Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:8640
34GF Score
Nomad Power Solutions Inc STU:8640
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nomad Power Solutions Business Description

Other Exchanges LIXT:USA
Address 433 Plaza Real, Suite 275, Boca Raton, FL, USA, 33432
Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The company's drug product pipeline is focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. Its product is LB-100 for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer. The company operates in a single reportable segment, which consists of the development of cancer treatments.
34GF Score

Get the complete analysis for STU:8640

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.00
Price